Sai Life Sciences Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Sai Life Sciences Ltd filed with BSE on 12 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Sai Life Sciences reported Q1 FY27 revenue of INR553 crores, up about 12% year-over-year, with CRO revenue growing 26% and CDMO growing about 6%. Management said the quarter's performance was in line with expectations and reiterated confidence in a stronger second half driven by planned capacity expansion. The company discussed progress on peptides, XDC, formulation and AI initiatives, and reaffirmed its longer-term revenue growth and EBITDA margin guidance.
Numbers mentioned
Revenue: INR553 crores (Q1 FY27)
p. 6
“For the quarter-ended Q1 FY27, total revenue stood at INR553 crores, representing a year-on-year increase of about 12% compared to INR496 crores in the same quarter last year.”
Siva Chittor, page 6 of the filed PDF · View the filing
CDMO revenue growth: about 6% (Q1 FY27 Y-o-Y)
p. 6
“On a Y-o-Y basis, CRO revenues increased by about 26% while the CDMO revenues grew by around 6%.”
Siva Chittor, page 6 of the filed PDF · View the filing
CDMO share of revenue: approximately 60% (Q1 FY27)
p. 6
“The CDMO business contributed approximately 60% of our revenues and the CRO business remaining 40%.”
Siva Chittor, page 6 of the filed PDF · View the filing
Active commercial molecules: 33
p. 6
“the underlying health of the CMC business continues to be strong with 33 active commercial molecules and 14 molecules in late phase.”
Siva Chittor, page 6 of the filed PDF · View the filing
Late phase molecules added: six (last 15 months)
p. 6
“Over the last 15-months, we have added six late phase molecules to our pipeline, 5 of which have come through large pharma clients with whom we have ongoing FTE engagements.”
Siva Chittor, page 6 of the filed PDF · View the filing
Returning customer revenue share: over 90% (FY25 and FY26)
p. 7
“We continue to add new customers, but returning customers accounted for over 90% of our revenue in FY25 and FY26.”
Siva Chittor, page 7 of the filed PDF · View the filing
FDA-approved molecules contributed to: five (calendar 2025)
p. 7
“In calendar 2025, Sai contributed to five FDA-approved molecules, meaning we were part of either discovery or development or commercial manufacturing for the product.”
Siva Chittor, page 7 of the filed PDF · View the filing
Launches supported: 17 (past five years)
p. 7
“Over the past five years, we have supported 17 launches, demonstrating our ability to supply launch quantities and play a meaningful role in commercialization.”
Siva Chittor, page 7 of the filed PDF · View the filing
Integrated services adoption among discovery customers: approximately 65%
p. 6
“Those investments in infrastructure, technology, and people are now translating into integrated service delivery for approximately 65% of our customers, today primarily biotech customers.”
Siva Chittor, page 6 of the filed PDF · View the filing
Peptide program spend by end 2028: less than INR300 crores (through end of 2028)
p. 17
“Dhaval, it's probably going to be less than INR300 crores.”
Siva Chittor, page 17 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 15% to 20% · three-to-five-year period
stated firmly by Siva Chittor
p. 14
“We have provided a revenue growth guidance of 15% to 20% over that period, and that remains our stated position.”
Siva Chittor, page 14 of the filed PDF · View the filing
EBITDA margin — 28% to 30%
stated firmly by Siva Chittor
p. 7
“We remain confident in our ability to sustain our longer-term revenue growth guidance of 15% to 20%, and the EBITDA range of 28% to 30%.”
Siva Chittor, page 7 of the filed PDF · View the filing
H2 vs H1 revenue — H2 FY27
stated firmly by Krishna Kanumuri
p. 3
“As we have discussed in the previous earnings call, we expect a stronger H2 with planned capacity expansion going live in the second half of the year.”
Krishna Kanumuri, page 3 of the filed PDF · View the filing
FY27 capex — INR1,100 crores to INR1,300 crores · FY27
stated firmly by Siva Chittor
p. 10
“we have given a FY27 capex guidance of INR1,100 crores to INR1,300 crores. That still stands.”
Siva Chittor, page 10 of the filed PDF · View the filing
Large pharma customer transitions to integrated model — at least two large pharmaceutical customers · this year
stated as an aspiration by Siva Chittor
p. 6
“We are already in discussions with several large pharmaceutical companies and hope to transition at least two large pharmaceutical customers to integrated models this year.”
Siva Chittor, page 6 of the filed PDF · View the filing
Large pharma FTE engagement close — by end of Q2, work from Q3
stated firmly by Siva Chittor
p. 7
“We've also begun negotiations for another large pharma FTE engagement on the process development side, which we expect to close by the end of Q2, with work expected to commence from Q3.”
Siva Chittor, page 7 of the filed PDF · View the filing
Peptide manufacturing facility — operational · 2028
stated firmly by Krishna Kanumuri
p. 4
“In addition, we plan to break ground for a peptide manufacturing facility at our new greenfield site near Hyderabad, which is expected to be operational in 2028.”
Krishna Kanumuri, page 4 of the filed PDF · View the filing
Formulation capability readiness — operationally ready · about six months / current fiscal year
stated firmly by Krishna Kanumuri
p. 4
“While we are still about six months away from being operationally ready, we are seeing significant interest from our pharma partners.”
Krishna Kanumuri, page 4 of the filed PDF · View the filing
Bidar production block completion — first 225 KL block operational · H2 / Q3
stated firmly by Siva Chittor
p. 12
“We had talked about plants getting completed and ready for operation in H2 or Q3.”
Siva Chittor, page 12 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the relationships are progressing over a 5-10 year horizon and that acceleration in scale and scope is being seen even though the evolution is still early.
Answered by Krishna Kanumuri
Asked by Binay Singh: Has the strengthening of big pharma relationships and integrated CRDMO trend accelerated this calendar year or is it a continuation of last year's trend?
p. 8
“While this evolution is still at an early stage, we are already seeing acceleration in both the scale and scope of services being offered.”
Krishna Kanumuri, page 8 of the filed PDF · View the filing
Management confirmed that FY26 was an unusual roughly 48/52 split versus the historical 40/60, and that they wanted to flag the expected skew in advance.
Answered by Krishna Kanumuri
Asked by Binay Singh: Is the stronger H2 skew this year due to more capacity coming online compared to the historical 40/60 split?
p. 8
“Historically, it has been more of a 40/60, but fiscal ’26 was almost flat. Hence, we wanted to provide some advance indication of how we are seeing our next year.”
Krishna Kanumuri, page 8 of the filed PDF · View the filing
Management said they don't quantify individual customer contributions and noted multiple customers, not just one, expanded collaboration this quarter.
Answered by Krishna Kanumuri
Asked by Amey Chalke: What drove the conversion of a large CRO customer and how significant is this relationship?
p. 9
“But it's just not one, we've converted a couple this quarter.”
Krishna Kanumuri, page 9 of the filed PDF · View the filing
Management said three of the four will be commercial supplies, they are primary in two of the three, and the size of the products is decent relative to Sai's revenue base, with one being lower volume.
Answered by Siva Chittor
Asked by Amey Chalke: For the four new commercial contracts, will Sai be primary or secondary supplier and what is the revenue size?
p. 9
“I think we probably are primary in two out of this three, but this is more anecdotal than what I can tell you at this point in time.”
Siva Chittor, page 9 of the filed PDF · View the filing
Management reiterated the FY27 capex guidance and said FY28 guidance would be provided later.
Answered by Siva Chittor
Asked by Akshay: What is the capex guidance for FY27 and FY28?
p. 10
“We haven't provided a guidance on fiscal '28. We will come back to you with a guidance at an appropriate time.”
Siva Chittor, page 10 of the filed PDF · View the filing
Management said the stated intent of pharma partners is generally to keep the program with Sai through commercialization, barring capacity mismatches.
Answered by Krishna Kanumuri
Asked by Sajal Kapoor: Does early involvement through dedicated FTE teams increase the probability of retaining molecules for commercial manufacturing?
p. 11
“The first intent of every pharma company is to leave the program with us for commercial.”
Krishna Kanumuri, page 11 of the filed PDF · View the filing
Management said the guidance reflects a three-to-five-year view given business lumpiness, and that they are not deliberately constraining growth, noting last year's growth was closer to 30%.
Answered by Siva Chittor
Asked by Karan Gupta: Given the large pipeline, why is growth guidance constrained to 15-20%?
p. 14
“We have provided a revenue growth guidance of 15% to 20% over that period, and that remains our stated position.”
Siva Chittor, page 14 of the filed PDF · View the filing
Management declined to discuss the mAb strategy or disclose fermentation capex details.
Answered by Krishna Kanumuri
Asked by Tirumala Reddy: Why hasn't Sai entered monoclonal antibodies (mAb) space, and what is the fermentation capex contribution?
p. 14
“We are not giving information on fermentation at all.”
Krishna Kanumuri, page 14 of the filed PDF · View the filing
Management said new modality work is present in development and discovery but not yet commercial.
Answered by Siva Chittor
Asked by Yasser Lakdawala: Are new modality revenues concentrated in CRO or also in development and commercial work?
p. 15
“We are not doing it on the commercial side, but we are doing on all the development and the discovery side.”
Siva Chittor, page 15 of the filed PDF · View the filing
Management said current work is mostly early-stage discovery across multiple customers, with a broader GMP pilot facility coming online sooner and true commercial capacity coming in 2028.
Answered by Krishna Kanumuri
Asked by Dhaval: How many peptide projects and customers are being worked on, and what is the 2028 facility for?
p. 16
“What we're building out for 28 is the true commercial capacity. So clinical capacity is coming online sooner, and commercial capacity is coming online 2028.”
Krishna Kanumuri, page 16 of the filed PDF · View the filing
Risks flagged
Business lumpiness affecting quarterly revenue trends
p. 7
“Notwithstanding the inherent lumpiness in the business, the long-term opportunity for the CRDMO sector remains robust”
Siva Chittor, page 7 of the filed PDF · View the filing
High failure rate of molecules at Phase 1 and Phase 2 limiting predictability of pipeline conversion
p. 13
“We mentioned this before, the number of exits at Phase 1 and Phase 2 is fairly huge.”
Siva Chittor, page 13 of the filed PDF · View the filing
Capacity mismatches could cause programs not to stay with Sai through commercialization
p. 11
“So I think it's only in the cases where there must be maybe a mismatch in capacity, but the primary intent, a stated intent is to leave it with Sai all the way through the life cycle of the product.”
Krishna Kanumuri, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.